Aporo Biomedical

Aporo Biomedical is a medical device company specializing in the development of transcatheter solutions for structural heart disease, specifically targeting mitral valve repair. The company was founded by Dr. William Cohn, a prominent cardiovascular surgeon and inventor, and was developed within the Texas Medical Center (TMC) ecosystem in Houston. Its primary technology is a novel transcatheter mitral valve repair system intended to provide a less invasive treatment option for patients suffering from mitral regurgitation. The device is designed to simplify the repair process and improve clinical outcomes for patients who are not ideal candidates for traditional open-heart surgery. In May 2018, the company was acquired by Edwards Lifesciences, a global leader in patient-focused medical innovations for structural heart disease. This acquisition allowed Edwards to further expand its portfolio of transcatheter mitral and tricuspid therapies (TMTT).